Protocol CACZ885M2301: A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-Myocardial Infarction Patients with Elevated hsCRP

Project: Research project

Project Details

StatusFinished
Effective start/end date10/11/1110/31/18

Funding

  • Novartis Pharmaceuticals Corporation (Prot # CACZ885M2301)